Holen Sie sich die Stockscreener-App
24.88
0.44%
0.11
Vorhandelsmarkt:
24.61
-0.27
-1.09%
Schlusskurs vom Vortag:
$24.77
Offen:
$24.22
24-Stunden-Volumen:
37.79M
Relative Volume:
1.29
Marktkapitalisierung:
$5.67B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
47.65
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+12.27%
1M Leistung:
+52.64%
6M Leistung:
-51.11%
1J Leistung:
-24.92%
1-Tages-Spanne:
$23.52
$25.16
1-Wochen-Bereich:
$22.43
$27.54
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
24.88 | 5.67B | 2.35B | 128.37M | 57.42M | 0.5221 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.56B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
118.15 | 49.87B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.46 | 46.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.46 | 34.31B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
534.30 | 23.42B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Aquatic Capital Management LLC Purchases New Stake in Hims & Hers Health, Inc. $HIMS - MarketBeat
HIMS: Leerink Partners Raises Price Target to $25.00 | HIMS Stoc - GuruFocus
Hims And Hers Health Pushes Into Complex Care And Global Growth - Yahoo Finance
HIMS Expands Personalized Digital Healthcare Access and Services - The Globe and Mail
Hims & Hers Health Stock Slips After Surging 50% In A Month - Benzinga
Novo Nordisk & Hims & Hers: Supply Deal for Ozempic and WegovyNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
What is behind Hims & Hers Health stock's recent drop in value today - Traders Union
Why the Novo Nordisk and Hims & Hers deal is a win for both stocks - MSN
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks - Yahoo Finance
Farallon Capital Management LLC Purchases 2,533,271 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Hims & Hers under fire over copycat weight loss drugs - WNTZ-TV FOX 48
Hims & Hers Health (HIMS) Is Up 57.4% After Renewed Novo Nordisk GLP-1 PartnershipHas The Bull Case Changed? - simplywall.st
Hims & Hers Stock Soars on Strategic Pivot with Novo Nordisk - AD HOC NEWS
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now? - Insider Monkey
Hims & Hers (HIMS) Soars 57.4% on New Deal - Insider Monkey
A Look At Hims & Hers Health (HIMS) Valuation After A Sharp 57% Weekly Share Price Move - simplywall.st
Hims & Hers posts best weekly gain after Novo deal - Seeking Alpha
OWL, HIMS, TSLA And More: 5 Stocks Investors Couldn't Stop Buzzing About This WeekOracle (NYSE:ORCL) - Benzinga
Hims & Hers Health, Inc. Class A Trade Ideas — SWB:82W - TradingView
Telehealth Giant Hims Partners with Novo Nordisk After Dropping Legal Battle - Fine Day 102.3
Hims And Hers Health Weighs Eucalyptus Deal Against Growth And Valuation Risks - simplywall.st
Weekly Market Update: Stocks Slide as Financials, Consumer Cyclicals Fall - Morningstar
Hims & Hers Stock Skyrockets Amid Novo Nordisk Partnership - StocksToTrade
Hims Shares Notch Record Week as Novo Pact Spurs Optimism - Yahoo Finance
Hims & Hers (HIMS) sees analyst optimism following Novo resolution - MSN
Hims & Hers (HIMS) Sees Analyst Optimism Following Novo Resolution - Insider Monkey
Selling pressure pushes Hims & Hers Health stock lower in today's trading - Traders Union
Hims & Hers class action alleges semaglutide GLP-1 products falsely advertised - Class Action Lawsuits
Barclays raises PT on Hims & Hers Health (HIMS) stock - MSN
Hims shares set for record week as Novo partnership fuels optimism - Modern Healthcare
Barclays Raises PT on Hims & Hers Health (HIMS) Stock - Insider Monkey
Hims & Hers Health stock price steadies after wild Novo week as focus shifts to margins - TechStock²
Hims shares set for best week on record after new Novo Nordisk deal - Investing.com
Hims Shares Set for Record Week as New Novo Pact Fuels Optimism - Bloomberg.com
5 Best Day Trading Stocks to Buy Now - Insider Monkey
Hims & Hers Stock Jumps After Novo Nordisk Deal. What It Means for Drugmaker - TradingView
Investor relations - HIMS Investor Relations
12 Most Shorted Stocks to Buy in 2026 - Insider Monkey
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications - MSN
‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up - MedCity News
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market - Yahoo Finance
Hims & Hers stock takes a major hit amid multiple investigations and target cuts - StocksToTrade
Stock Market Today, March 12: Hims and Hers Health Drops After Rally Sparks Profit Taking - Yahoo Finance
Hims And Hers Benefits Aims To Deepen Member Loyalty And Engagement - simplywall.st
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Hims & Hers Faces Investigation Amid Wegovy Sales Discontinuation - timothysykes.com
Hims & Hers Plunges 29.4% in Three Months: How to Play the Stock? - The Globe and Mail
Hims & Hers Drops 29.4% Over Three Months: What’s the Best Strategy for This Stock? - Bitget
Hims & Hers Health hires Kathryn Beiser as chief communications officer - Medical Marketing and Media
Should You Chase the Rally in Hims & Hers Stock Today? - Barchart.com
Is Hims & Hers Really the Growth Stock to Buy That It Appears? - Yahoo Finance
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.37%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):